**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 65720

**Manuscript Type:** REVIEW

**Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity**

Pal P *et al*. Nonalcoholic fatty liver disease heterogeneity

Partha Pal, Rajan Palui, Sayantan Ray

**Partha Pal,** Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500082, India

**Rajan Palui,** Department of Endocrinology, The Mission Hospital, Durgapur 713212, West Bengal, India

**Sayantan Ray,** Department of Endocrinology, Jagannath Gupta Institute of Medical Sciences and Hospital, Kolkata 700137, West Bengal, India

**Sayantan Ray,** Diabetes and Endocrinology, Apollo Clinic, Ballygunge, Kolkata 700019, West Bengal, India

**Author contributions:** Pal P performed the literature search, wrote the first draft and provided intellectual input; Palui R conceptualized the work, performed a literature search, supervised the writing; Ray S supervised the literature search, the writing, provided intellectual input and critically revised the manuscript.

**Corresponding author: Sayantan Ray, MBBS, MD,** Department of Endocrinology, Jagannath Gupta Institute of Medical Sciences and Hospital, KP Mondal Road, Budge Budge, Kolkata 700137, West Bengal, India. sayantan.ray30@gmail.com

**Received:** March 14, 2021

**Revised:** July 29, 2021

**Accepted:** October 14, 2021

**Published online:** November 27, 2021

**Abstract**

Non-alcoholic fatty liver disease (NAFLD) is a heterogeneous condition with a wide spectrum of clinical presentations and natural history and disease severity. There is also substantial inter-individual variation and variable response to a different therapy. This heterogeneity of NAFLD is in turn influenced by various factors primarily demographic/dietary factors, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The differential impact of these factors over a variable period of time influences the clinical phenotype and natural history. Failure to address heterogeneity partly explains the sub-optimal response to current and emerging therapies for fatty liver disease. Consequently, leading experts across the globe have recently suggested a change in nomenclature of NAFLD to metabolic-associated fatty liver disease (MAFLD) which can better reflect current knowledge of heterogeneity and does not exclude concomitant factors for fatty liver disease (*e.g.* alcohol, viral hepatitis, *etc.*). Precise identification of disease phenotypes is likely to facilitate clinical trial recruitment and expedite translational research for the development of novel and effective therapies for NAFLD/MAFLD.

**Key Words:** Non-alcoholic fatty liver disease; Metabolic-associated fatty liver disease; Heterogeneity; Phenotypes; nomenclature; Clinical trial; Effective therapies

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Pal P, Palui R, Ray S. Heterogeneity of nonalcoholic fatty liver disease: Implications for clinical practice and research activity. *World J Hepatol* 2021; 13(11): 1584-1610

**URL:** https://www.wjgnet.com/1948-5182/full/v13/i11/1584.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v13.i11.1584

**Core Tip:** It is being increasingly recognized that non-alcoholic fatty liver disease (NAFLD) is a heterogenous condition with wide variability in clinical presentation and natural history. This heterogeneity is driven by genetic predisposition, metabolic factors, gut microbiota, diet and demographic factors. The suboptimal response to current pharmacotherapy in NAFLD highlights the failure to recognize this heterogeneity. Experts believe that updating NAFLD nomenclature is the first step towards this. Identification of disease subtypes can help development of preclinical model evaluating novel targets. This would in turn help clinical trial design by comparing and pooling results and thus improve disease outcomes.

**INTRODUCTION**

Non-alcoholic fatty liver disease (NAFLD) is increasing in both developed and developing countries, in parallel with the global obesity epidemic. Nevertheless, much is still unknown on the NAFLD phenotype. Moreover, since the term NAFLD was coined by Ludwig *et al*[1] in 1980, the nomenclature and diagnostic criteria have not been revisited. With a deeper understanding of the natural history of NAFLD, it has become gradually more obvious that this term is inherently complicated, chiefly due to the heterogeneity of NAFLD and principal driving factors between individuals. This heterogeneity in clinical presentation and the course of NAFLD is probably influenced by several factors which include age, gender, ethnicity, diet, alcohol consumption, genetic predisposition, microbiota, and metabolic milieu[2].The combined effect of the dynamic and complex systems-level interactions of these drivers is probably reflected in the phenotypic manifestations of NAFLD. Therefore, comprehensive phenotyping will translate into individual-level risk prediction and preventive strategies, and improvements in the design of clinical trials[2]. The heterogeneity of NAFLD and the presence of multiple pathophysiological pathways intrinsic to its progression suggest that the nomenclature should be revised and NAFLD may be classified in a way that takes into account the various underlying processes[3]. However, a change of name of any disease has considerable implications for both clinical practice as well as public health policy. Based on these evolving paradigms, this review will explore the factors contributing to NAFLD heterogeneity and its clinical and therapeutic implications. Besides, proposed changes in the current nomenclature and definition of NAFLD are discussed along with future perspectives.

**HETEROGENEITY OF NAFLD: NEED FOR A NEW TERMINOLOGY**

NAFLD represents an umbrella term with considerable heterogeneity among its subtypes. This is evidenced by variable disease severity and progression (disease phenotype) among patients with NAFLD[4]. The disease phenotype in NAFLD is in turn influenced by primary drivers of the disease and dynamic interaction between various disease modifiers (age, sex, ethnicity, co-existing disease, diet, alcohol consumption, smoking, hormonal status, genetic and epigenetic factors, gut microbiota, and metabolic risk factors)[2]. Although steatosis is highly prevalent, progression to steatohepatitis or other liver-related complications like cirrhosis and hepatocellular carcinoma (HCC) is highly unpredictable. The rate of fibrosis progression can also vary widely among patients. Moreover, there is growing evidence that HCC can develop in NAFLD without cirrhosis[5].

The suboptimal response rates of current investigational therapies (20%-40%) reflect a lack of consideration of heterogeneity of NAFLD[2,6]. Hence, a structured dissection of the key pathogenetic pathway and precise disease sub-typing based on genetic background, metabolic profile and anthropometric parameters shall help predict individualized risk and provide effective treatment[2]. The term NAFLD was coined in 1980 by Ludwig *et al*[1] and it was used to describe fatty liver disease without a history of significant alcohol intake. Although the prevalence of NAFLD has grown to epidemic proportions involving one-fourth of the population, the nomenclature and the diagnostic criteria have not been reevaluated[2]. The term NAFLD does not consider the heterogeneity of the disease and hence does not reflect current knowledge.

Based on recent epidemiological studies, it has been increasingly recognized that there is no cut-off for safe drinking in so-called NAFLD as there is frequent co-existence of at-risk drinking and dysmetabolism[7]. Moreover, accurate assessment of alcohol intake is often challenging especially in subpopulations like children and women due to cultural interdiction[8]. To further confuse the issue, there is evidence that an altered gut microbiome can lead to excess production of endogenous alcohol in non-drinkers[9]. Hence, the dichotomy between alcoholic liver disease and NAFLD should be abandoned. Until now, diagnosis of NAFLD was based on the exclusion of excess alcohol intake, concomitant viral hepatitis/other liver diseases, and secondary cause of fatty liver (*e.g.* drug-induced). With the increasing prevalence of NAFLD and the high prevalence of other liver diseases such as viral hepatitis particularly in countries like Middle East and north Africa, dual causes of liver disease should be considered[8]. The current definition of metabolic-associated fatty liver disease (MAFLD) does not require the exclusion of the above, considering the co-existence of different pathology for fatty liver disease (Figure 1). However, it requires the presence of overweight/obesity, type 2 diabetes mellitus (T2DM), or 2 metabolic risk factors. The term “non” in “nonalcoholic fatty liver disease” trivializes a disease that has major hepatic, cardiovascular (CV), and oncological sequelae[2,10]. Due to the “non”-rubric, it could be misinterpreted as something not serious and even encourage alcohol consumption. The term “alcohol” makes the nomenclature derogatory and thus stigmatizing the condition blaming the patient for their condition[2]. This has profound implications on recognition of the disease as a major public health problem and resource allocation by regulatory authorities to intercept this potentially deadly disease.

Due to the aforementioned reasons, the term MAFLD was proposed by Lonardo and Carulli 16 years back[11]. However, NAFLD nomenclature remained unchanged until now. For the same reasons, Polyzos and Mantzoros[12] have proposed the term dysmetabolism associated fatty liver disease (DAFLD). Recently two consensus guidelines have proposed a change in the nomenclature of NAFLD to MAFLD and have redefined the condition based on the presence of hepatic steatosis and metabolic risk factors[2,13] (Figure 2). The impact of such change was reflected in the identification of patients with hepatic steatosis with a higher risk of disease progression in a cross-sectional study of more than 13000 patients based on data from the third National Health and Nutrition Examination Surveys of the United States[14]. Another study from Hong Kong has shown that MAFLD definition reduces the incidence of fatty liver disease by 25% [more so in patients with low body mass index (BMI)], while the prevalence remains unchanged. Patients with a fatty liver disease not fulfilling the criteria of MAFLD were unlikely to have significant liver disease.

However, the future implications of change in the nomenclature are still unknown. Hence, Younossi *et al*[15], on behalf of the American Association for the Study of Liver Disease[15] have cautioned about the impact of premature change in terminology to MAFLD. While there are still existing challenges in widespread disease awareness, identification of treatment endpoints, and biomarkers for risk stratification, changing terminology may negatively impact the field[15]. Moreover, international consensus involving all scientific societies, regulatory bodies, pharmacological industry, and patient organizations is required before a change in terminology. No matter what is the terminology for fatty liver disease, it is clear that it is a heterogeneous disease with varying manifestations.

**NAFLD AND CARDIOVASCULAR RISK**

Patients with NAFLD are more likely to have morbidity and mortality from cardiovascular disease (CVD). Currently proposed term MAFLD is closely linked to DM, dyslipidemia, hypertension, systemic inflammation which are known to increase CVD risk. A higher risk of CVD and CVD associated events have been noted in epidemiological and observational studies in NAFLD[16,17]. NAFLD not only damages the coronary arteries (atherosclerosis and ischemic heart disease), but also the other cardiac structures like myocardium (heart failure), cardiac valves (aortic stenosis, mitral annular calcification), and conduction system (atrial fibrillation, conduction defects)[18]. CV disease in NAFLD can be subclinical (coronary and courted atherosclerosis) or clinical (myocardial infarction, stroke). Pathophysiological factors include dyslipidemia, oxidative stress, systemic inflammation, endothelial dysfunction, and a pro-thrombotic state leading to structural and functional cardiac changes including arterial stiffness, atherogenic plaque formation, and coronary calcification[19]. Among genetic factors related to NAFLD, MBOAT7 may promote venous thromboembolism whereas Transmembrane 6 superfamily 2 (TM6SF2) appears to be protective and PNPLA3 seems not to be associated with the risk of CVD. Other pathogenetic mechanisms of NAFLD such as environmental factors (diet, obesity, *etc.*), gut microbiota (through the gut liver axis and altered intestinal permeability), and epigenetic alterations also influence the CV risk[16].

Lifestyle modification and weight loss help in primary and secondary prevention of CVD in NAFLD. Aspirin and statins may be considered for primary and secondary prevention in individuals with NAFLD who are at high risk of CVD. Newer anti-diabetic medications such as SGLT2 inhibitors and GLP-1 receptor agonists are known to reduce CV events in T2DM and may be useful in this regard. Additional data are required on CV risk modification by farnesoid X receptor (FXR) agonists such as obeticholic acid. Future studies will likely address the predictive factors responsible for elevated CVD risk in NAFLD as there is a lack of targeted pharmacological therapy. Hence, CV endpoints should be included in clinical trials in NAFLD/MAFLD[16,19].

**FACTORS FOR HETEROGENEITY**

***Age***

The prevalence, risk of hepatic/extra-hepatic complications, and all-cause mortality of NAFLD increase with age. This is due to multiple factors like reduction in hepatic blood flow/volume, decrease in bile acid synthesis, altered cholesterol metabolism, increase in oxidative respiration due to decrease in mitochondria numbers, cellular aging, increased exposure to disease drivers over a prolonged period, and progressive increase in insulin resistance (IR) due to change in body composition (sarcopenia, abdominal and visceral adiposity with ectopic fat deposition)[20-23].

***Gender and menopause effect***

The prevalence of NAFLD and degree of hepatic fibrosis are lower in pre-menopausal women compared to men and postmenopausal women with better overall survival rates in the former[24]. Changes in body fat distribution (abdominal obesity after menopause), differences in metabolic risk factors, sexual dimorphism of key metabolic pathways (lipid metabolism, insulin signaling, and inflammation), and differences in hepatic gene expression of various metabolic pathways (*e.g.* FXR, liver X receptor) are likely mechanisms for the difference[25-27]. The prevalence of NAFLD and fibrosis risk is lower in postmenopausal women on hormone replacement therapy (HRT) compared to those who are not on HRT[28]. The extent of hepatic fibrosis increases with the prolonged duration of estrogen deficiency in postmenopausal women[29]. Hence, risk stratification in NAFLD should be based on gender and menopausal status.

***Ethnicity***

The prevalence of NAFLD and risk of nonalcoholic steatohepatitis (NASH) are seen in decreasing order of frequency in Hispanics, non-Hispanic whites, and African Americans[30]. It is important to note that the risk of fibrosis did not vary based on ethnicity. The plausible explanations for such racial disparity are differences in genetic predisposition, metabolic traits (IR and body fat distribution), environmental factors (dietary habits like increased carbohydrate consumption, physical inactivity, and cultural factors). For example, the frequency of risk alleles of Patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) gene in Hispanics, non-Hispanic whites, and African-Americans are 49%, 23%, and 17% respectively[31]. Importantly, Asian individuals tend to accumulate liver fat at lower BMI, have a higher degree of inflammation, and have a possibly higher risk of fibrosis compared to other ethnicities[32,33]. PNPLA3 rs738409 risk allele frequency is more common in East Asians compared to Caucasians[34].

***Diet and gut microbiota***

It is well known that a Western diet with high fat and fruit content leads to a higher incidence of NAFLD. On the other hand, the adoption of the Mediterranean diet is associated with decreased liver fat content and CV risk[35]. Gut microbial composition changes rapidly according to changing dietary patterns. The effect of diet in fatty liver disease is difficult to differentiate from those due to diet-induced change in gut microbial composition[36]. Gut microbiome composition can identify individuals with a higher risk of NAFLD progression[37]. The gut microbiome and its metabolites influence bile acid metabolism, which in turn influences lipid, choline, and glucose metabolism. Alteration in gut microbial composition and intestinal permeability in NAFLD leads to the circulation of bacterial metabolites such as lipopolysaccharide which is in turn sensed by hepatic Toll-like receptors which induce activation of hepatic pro-inflammatory cells and stellate cells leading to inflammation and fibrosis progression[38,39]. Apart from dietary factors, genetic makeup and ethnicity influence gut microbiome composition[40,41].

***Metabolic health***

**Obese *vs* lean NASH:** Although intra-hepatic fat content is closely influenced by obesity, 45% of the obese are said to be metabolically healthy as they don’t have any components of metabolic syndrome (MetS)[42]. It is not clear whether these individuals have a lower risk of CV complications compared to normal-weight, metabolically healthy individuals[43]. On the other hand, 30% of normal-weight individuals have MetS and higher cardiometabolic risk. This is because the distribution and nature of fat are more important than the amount of fat in predicting metabolic risk[2]. Visceral fat is associated with higher metabolic risk compared to peripheral and subcutaneous fat. Fat distribution is influenced by ethnicity (higher visceral adiposity in Asians) and genetic makeup[44]. 5%-45% of NAFLD (20% among Europeans) are also lean NAFLD as defined by the presence of hepatic steatosis with normal BMI in the absence of significant alcohol intake[45]. Lean NAFLD has distinct genetic predisposition, metabolic and microbial profiles. Increased prevalence of TM6SF2 risk allele, increased bile acids/Farnesoid receptor activity due to intact metabolic adaptation, and gut microbial profile which facilitates liver fat generation have been seen in lean NAFLD. Individuals with lean NALFD have a better metabolic profile compared to their obese counterparts[46]. The data on the natural history of disease progression in lean NAFLD have shown variable outcomes. Distinct pathways of liver fat accumulation are being recognized. In type 1/metabolic NAFLD, calorie excess due to dietary intake and physical inactivity leads to increased hepatic fatty acid supply by peripheral lipolysis and hepatic lipogenesis[4]. This is associated with IR and other components of MetS thus leading to increased cardiometabolic risk. The accumulated liver fat is composed of monounsaturated triacylglycerols and free fatty acids enriched with ceramides. In type 2/PLNPLA3 NAFLD (with rs738409 risk allele), there is increased intra-hepatic lipogenesis and impaired lipolysis leading to steatosis[47]. The fat composition is predominantly polyunsaturated triacylglycerols. This is not associated with IR and adverse cardiometabolic outcomes although the risk of NASH and HCC is increased. Increasingly various metabolomic signatures leading to hepatic steatosis are being recognized based on RNA-sequencing analysis study[48]. Identification of the key pathway for hepatic steatosis by genetic and molecular profiling may thus help in predicting the risk of progression, cardio-metabolic, and treatment outcomes.

***Genetics and epigenetics***

Among the multiple variant genes associated with NAFLD identified on genome-wide association studies, few common variants (PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13) are worth mentioning which have divergent metabolic effects[49]. PNPLA3 and TM6SF2 variants increase the risk of NAFLD and advanced fibrosis[50,51]. PLPLA3, TM6SF2, and GCKR variants are associated with T2DM[52]. MBOAT7 and HSD17B13 variants do not affect serum lipid or glucose levels and do not increase cardiometabolic risk[53,54]. These variants explain only a minority of NAFLD. That is why it is important to consider the effect of other variants, gene-environment interactions (described with the *PNPLA3* gene), and epigenetics. Epigenetic alterations of key regulators of metabolic, inflammatory, and fibrotic pathways represent a bridge between variant genes and the environment in NAFLD. Micro-RNAs such as miRNA-122, miRNA-192, and miRNA-34a are unregulated in NAFLD[55]. miRNA-34A also correlates with disease activity. The role of long non-coding RNAs (lncRNAs) in NAFLD is limited requiring further elucidation[56]. Reversible alteration of methylation signatures of key regulatory pathways is seen in NAFLD which reverses following weight reduction surgery[57]. Methylation signatures can help identify patients with advanced fibrosis [*e.g.* hyper-methylation of peroxisome proliferator-activated receptor gamma (PPARγ)][58]. Epigenetic alterations can alter the expression of PNPLA3 explaining the gene-environment link[59]. There is increasing evidence that maternal high fat diet leads to epigenetic alterations in fetal liver and increasing the possibility of NAFLD in adolescence in the offspring[60,61]. Higher maternal BMI is associated with hypermethylation of the PPARγ coactivator 1(*PGC1*) gene which regulates energy metabolism in the newborn[62].

***Familial risk***

Twin studies, prospective and retrospective family studies have shown heritable factors in hepatic steatosis and fibrosis. In a prospective study, the risk of advanced fibrosis in first-degree relatives of patients with NAFLD-cirrhosis was 18% which is significantly higher than the general population risk[63,64]. Hence family history also should be considered while doing risk stratification of NAFLD patients.

***Alcohol intake***

The effect of alcohol use in fatty liver disease has a dose-dependent response which synergistically increases in the presence of metabolic risk factors[65]. This is contrary to the earlier belief that alcohol consumption has a “J” shaped effect on fatty liver disease progression with a beneficial effect on light to moderate use and deleterious effect on excessive use[66]. Hence, it is being increasingly revealed that there is no safe cutoff of alcohol consumption in fatty liver disease.

**CLINICAL IMPLICATIONS OF NAFLD HETEROGENEITY**

***NAFLD sub-classification***

The heterogeneity in NAFLD due to its multifactorial etiology, pathophysiological diversity, genetic polymorphisms, and on the other side, the ultimate unifying fate of steatosis and its progression, made NAFLD more like an umbrella disease with multiple subtypes. The proposed change of nomenclature as MAFLD, will not truly represent the full spectrum of the disease pathophysiology and thus this over-generalized new nomenclature has been criticized. Singh *et al*[3] had proposed the ‘MEGA-D’ classification representing the ‘Mega-diversity’ of the NAFLD. They had proposed five sub-types of the disease, each representing a major pathophysiological hypothesis behind each subtype. The subtypes are as follows: M-Metabolic syndrome, E-Environmental stressor, G-Genetic Factor, A-Bile Acid dysregulation, and D-Gut dysbiosis related NAFLD. Moreover, it is also suggested to consider fatty liver disease as an umbrella term to include the whole spectrum of cryptogenic to classic to alcohol-associated fatty liver disease. Till any consensus-driven widely accepted terminology and sub-classification of NAFLD comes into place, it is prudent to consider fatty liver disease as common outcome pathology with different etiological triggers.

Alteration of lipid metabolism is one of the major pathophysiological factors behind the development and progression of NAFLD. Lipidomics based sub-classification of patients with NAFLD had been proposed which depends upon the signature patterns of alteration in the fatty acid homeostasis pathway[67]. ‘M-subtype’ is characterized by increased hepatic fatty acid uptake and reduced hepatic glutathione and S-adenosine methionine (SAM) content. On the other hand, the ‘non-M subtype’ occurs due to increased de novo hepatic lipogenesis and is characterized by normal hepatic SAM levels. Gut microbiota composition-based sub-classification of NAFLD had also been proposed. However, till now no studies had been able to reveal any signature gut microbiota profile suitable for phenotypical classification of NAFLD patients.

Automated algorithm-driven cluster sub-classification, based on demographic factors (age, gender, ethnicity), clinical and laboratory findings[68], had been evaluated in a cohort of 13290 NAFLD patients in the United States. The whole cohort had been divided into 5 subtypes and evaluated for disease outcomes including survival rates. In subtype 1, there were mostly female Hispanics with mild metabolic comorbidities with minimal fibrosis, but on the other hand subtype 2 had mostly patients with MetS with signs of developing liver dysfunction. Subtype 3 was a mostly young and healthy population with mild disease and minimal abnormalities. Subtype 4 patients were predominantly elderly male Caucasians who had more severe disease at baseline with features of fibrosis and also showed features of progression to cirrhosis stage. Subtype 5 patients were the oldest with more severe cirrhosis and associated with significant co-morbidities. Among the disease outcome, subtype 5 was at the highest risk mortality and subtype 4 had the highest risk of cirrhosis and HCC. Although this type of cluster-based subtyping of the disease needs to be validated clinically it can help to identify relevant disease subtypes in future studies.

In a gene expression study by Hoang *et al*[48], the disease progression score of individual genes had been evaluated and it showed a strong correlation with histological manifestations of disease severity. In this study, the authors proposed NAS (gene-level NAFLD activity score) and gene-level fibrosis stage (gFib) scores. These score-based subtypes of NAFLD not only can assess the risk of disease progression but also can predict the response to therapy. This molecular-based cluster classification either can be the forerunner of different clinical subtypes of NAFLD or can represent different phases of a dynamic spectrum of the disease.

Though genetic, clinical cluster, and pathophysiological based sub-classification of NAFLD had been proposed as discussed above, none of them are universally accepted. Moreover, detailed literature is mainly limited to disease phenotypes depending upon demographic factors, obesity, and clinical outcomes.

***Inter-individual variation***

**Demography (Asian *vs* Western countries):** The prevalence of NAFLD is now showing an increasing trend in Asian countries. A meta-analysis done in 2016[69] showed a higher prevalence in Asia (27.4%) than North America (24%) or European Union (23.7%). In a recent meta-analysis[70], the prevalence in Asia was found to have increased further (29.62%) and a secular trend of the rising prevalence in the last few decades had been reported. The increase in prevalence in Asia is likely due to an increase in obesity, sedentary lifestyle, changing westernized eating habits, and various socio-economic factors[71]. The prevalence in the rural area was significantly lower than in the urban areas, suggesting the detrimental effect of urbanization on obesity and the consequent NAFLD[72]. In both Asian and western countries, the prevalence increases with age. Prevalence is higher in males as well as among elderly women indicating protective effects of estrogen in females in the reproductive age group. Apart from the increased prevalence of metabolically unhealthy obesity and excessive visceral obesity, alteration of gut microbiota and bile acid profiles has also been postulated as possible contributing factors behind the development of steatosis[40]. Among the genetic factors, PNPLA3 polymorphism (rs738409) had been strongly associated with hepatic steatosis in both western and eastern studies[31]. However, a higher prevalence of PNPLA3 risk allele had been reported in Asia than in African or European countries[73,74]. Genetic polymorphisms of other genes like *TM6SF2*, *AGTR1*, *HSD17B13*, and *GCKR* genes had also been linked with increased susceptibility of NAFLD in Asian subjects[54,75-77]. Sarcopenia and hypovitaminosis D also was associated with NAFLD development[78,79]. One of the major differences in Asian countries from their western counterpart is the increased prevalence of lean NAFLD (discussed later) in the former. Though the overall prevalence of NAFLD is almost similar in eastern and western countries, however, the rate of complications is still lesser in Asian countries. In a retrospective study from Japan with a median follow-up of 5.8 years, only 0.25% of patients developed HCC with an annual incidence of 0.043%[80]. In contrast to western countries, NAFLD still contributes only to a minor proportion of liver-related complications requiring liver transplantation in Asia. In a Japanese nationwide survey, only 2.1% of patients with cirrhosis had NASH and almost two-thirds of the patients had viral hepatitis[81]. The indolent course of NAFLD in Asian countries is likely due to relatively short disease duration in the majority of the patients in this part of the world. As there is a considerable lag in economic growth and consequent obesity epidemic in Asian countries, the rise in NAFLD and its complications are likely to follow the western trend in the coming years. Moreover, the relatively higher chance of co-existence of viral hepatitis and NAFLD in Asian countries increases the risk of hepatic complications further[82].

**Ethnicity:** Irrespective of ethnic variability, a trend of overall increased prevalence of NAFLD had been seen globally. In the world, Middle East had the highest prevalence of NAFLD, and in Africa; it is the lowest[69]. Studies from the United States reported that Hispanics had shown the highest risk of NAFLD and on the other hand, the risk is much less in the Alaskan Native. Among Asian ethnicity, the prevalence is highest among Indonesian and lowest in Japanese[70]. Interestingly, people of South Asian origin who are living in the United Kingdom, also showed higher risk[83]. In a recent meta-analysis, which evaluated ethnic heterogeneity of NAFLD in the United States, both higher overall prevalence of NAFLD and risk of progression to NASH had been reported in Hispanics and the risks were lowest among Blacks[30]. Although there was no significant difference in patients with fibrosis among different ethnicities. The reasons behind the ethnic variation are multifactorial. A significantly high risk of NAFLD among American Japanese than the native Japanese suggests the impact of socio-economic development and differences in lifestyles in the pathogenesis[70]. Specific western dietary patterns in different ethnicities, like consumption of red meat and hydrogenated fat, had also been associated with an increased risk of fibrosis[84]. Intake of saturated fatty acids increases and on the other hand, consumption of omega 3 fatty acid-rich food reduces the risk of steatosis. Genetic factors can explain the heterogeneity of NAFLD across different ethnicities. Among genetic variants of the *PNPLA3* gene, rs738409 increases the risk of NAFLD in Hispanics and Southeast Asians[85]. On the other hand, the increased prevalence of protective polymorphism of the same *PNPLA3* gene (rs6006460) can explain the reduced risk of NAFLD among African Americans[31]. The rs738409 variant had been also associated with an increased risk of progression to NASH and hepatic fibrosis[86,87]. However, in a study from Malaysia, though the frequency of *PNPLA3* risk allele was higher among Chinese individuals but the prevalence of NAFLD was much less in them in comparison to Malay and Indian participants[87]. This paradox can be explained by the involvement of multiple candidate genes in disease pathophysiology among different ethnicities. With the advent of Genome Wise Association studies, the role of predisposing polymorphisms of other candidate genes like *TM6SF2* and *GCKR* gene had been explored further. The rs58542926 variants of the *TM6SF2* gene were significantly associated with intra-hepatic fat (triglyceride) accumulation in White and African-American but not among Hispanic individuals[88]. Different polymorphisms in the *AGTR1* gene were protective among Indians but not in Chinese and Malay subjects[75]. Recently, polygenic gene scores had been developed to evaluate the cumulative effects of multiple candidate genes in the development and progression of NAFLD[89]. Further studies are needed in the future to explore the complex interaction of different genetic polymorphisms which can explain disease heterogeneity across different ethnic populations.

**Age (Children and adolescents):** With the increasing prevalence of pediatric obesity, the prevalence of NAFLD in children and adolescents is ever rising. The pooled prevalence of pediatric NAFLD in general population and obesity clinic were 7.6% (95%CI: 5.5%-10.3%) and 34.2% (95%CI: 27.8%-41.2%) respectively[90]. The factors which can influence the intrauterine metabolic milieu of the developing fetus, like maternal obesity and diabetes, had been postulated to increase the future risk of NAFLD[91,92]. Increased consumption of fructose-rich beverages, processed food, saturated fat along with decreased intake of dietary fibers (westernized dietary habits) had been strongly associated with the development of NAFLD in children[93]. On the other hand, breastfeeding was protective against the development of NAFLD[94]. The genes which had been shown to increase the risk of pediatric NAFLD are similar to the adults. Genetic variants of*PNPLA3* (rs738409), *TM6SF2* (rs58542926), and *GCKR* gene had been shown to increase the susceptibility of development of NAFLD in pediatric patients[31,88]. Though histological diagnosis of NAFLD remains ideal, diagnosis by imaging (ultrasound/MRI) is the most practical one in the pediatric population. As the prevalence of obesity in children is ever-increasing, the chance of co-existence of other secondary causes of hepatic steatosis should also be carefully evaluated before confirming the diagnosis of NAFLD. Histological pattern in pediatric NAFLD (peri-portal distribution-Type 2 NASH) differs from that of their adult counter-part (peri-central distribution-Type 1 NASH)[95]. Both fibrosis and steatosis are mainly present in the periportal region in type 2 NASH and are seen more in younger children. Moreover, the classical ‘ballooning’ change is also seen less frequently in children. On the other hand, type 1 NASH of the adult pattern can be seen in the older adolescent age group[96]. There is a paucity of longitudinal studies evaluating the natural history of pediatric NAFLD. Around 10%-25% of patients had advanced fibrosis and almost half of the patients had NASH at the time of diagnosis[97]. Though the incidence of HCC in the pediatric age group is extremely rare, a large number of pediatric patients with NAFLD are at increased risk of developing HCC in early adulthood. Weight loss and lifestyle changes were effective in the reversal of steatosis in pediatric patients[98].

**BMI (lean/non-obese NAFLD):** Lean and non-obese NAFLD is defined as NAFLD in a person with BMI < 25 kg/m2 (< 23 for Asian subjects) and < 30 kg/m2 (< 25 for Asian subjects) respectively. In a meta-analysis that included 93 studies from 24 countries, the prevalence of lean and non-obese NAFLD in the general population was reported as 5.1% and 12.1% respectively[99]. Globally, the prevalence of non-obese NAFLD among the whole NAFLD group was 40% and in countries like India, it is as high as 47%, indicating that a large proportion of fatty liver disease is now developing in the non-obese population. Though non-obese NAFLD initially was more common in Asian countries, now almost similar prevalence of NAFLD is being reported from the western part of the world (United States 43.2%). Globally the prevalence of lean/non-obese NAFLD is showing an increasing trend over the last 3 decades[100]. Though Shi *et al*[101] had reported a lower prevalence of hypertension, hyperuricemia, and fasting blood glucose in lean/non-obese NAFLD patients compared to obese NAFLD, these lean patients are not necessarily metabolically healthy. Rather lean NAFLD patients are more likely to have visceral obesity, metabolic syndrome, dyslipidemia, hypertension, and DM as co-morbidities than the lean controls[101]. The pathophysiological basis of the development of NAFLD in lean/non-obese individuals is complex and multi-factorial. Increased prevalence of the PNPLA3 G allele had been found in lean NAFLD patients[102]. Other genetic factors like TM6SF2 (T)[46], cholesteryl ester transfer protein, and interferon lambda 3 (IFNL3)/IFNL4(C) had also been found to increase the risk of lean/non-obese NAFLD[103,104]. On the other hand, possible roles of distinct gut microbiota, bile acid profile[46,105], increased lysine, tyrosine, lysophosphatidylcholines, and phosphatidylcholines, had also been implicated in the development of NAFLD among lean individuals[106]. The progression of NAFLD in the lean population can be conceptualized as a state of gradual attenuation of metabolic adaptation. Pathophysiologically, this can be divided into 3 stages- stage of susceptibility, stage of adaptation, and stage of failure[107]. Studies evaluating the true natural history of lean NAFLD are sparse in the literature. In the largest meta-analysis Ye *et al*[99] reported that among lean/non-obese NAFLD patients, NASH and fibrosis (> stage 2) were present in 39% and 29% of patients respectively, which was lesser than the prevalence among obese NAFLD population. However, liver-related mortality was reported as almost twice in lean/non-obese NAFLD patients than in the obese NAFLD group. In another study with a mean longitudinal follow-up of almost 20 years, lean NAFLD patients did not show any significantly increased risk of overall mortality but the risk of progression to severe hepatic diseases was significantly higher (HR 2.69) than the obese NAFLD population[108]. Like obese NAFLD, lifestyle modification in the form of dietary modifications and increased physical activity remains the main therapeutic approach in lean NAFLD patients[109].

***Variable natural history***

**Classic and dynamic model:** Previously, the natural history of NAFLD had been conceptualized as a disease spectrum that follows a linear model of disease progression. This classic model hypothesized that there is a gradual progression of the disease from NAFL to NASH to cirrhosis and HCC. However, this progressive worsening of the disease does not occur in all of the patients of NAFLD and significant heterogeneity in the natural history of NAFLD had been observed. Recent literature had identified that not all the patients with NAFLD follow this ‘classic linear model’ of natural history. A study by Pais *et al*[110], which systemically evaluated serial liver biopsy in NAFLD patients, had shown that 60% of NAFL patients had progressed to NASH and around 25% of patients of NAFL had directly progressed to the fibrotic stage. Various factors like DM, obesity, old age, and a higher degree of baseline abnormality were identified as possible risk factors for disease progression. In another longitudinal follow-up study by McPherson *et al*[111], no significant difference in the rate of fibrosis progression between NAFL and NASH patients was found. In an excellent systematic review by Singh *et al*[112], serial liver biopsy data of 411 biopsy-proven NAFLD from 11 cohort studies were analyzed. They had also re-emphasized that both NAFL and NASH can progress to the fibrotic stage. However, it takes much longer (14 years) time to progress one fibrosis stage in NAFL than in NASH (7 years). The annual fibrosis progression rate was slower in NAFL (0.07 stage) than in NASH (0.14 stage). Moreover, NAFL and NASH had a comparable rate of CV mortality (OR 0.9) though all-cause and liver-related mortality are higher in NASH[113]. To summarize, NAFL can progress both to the NASH and fibrosis stage directly and on the other hand, NASH can also regress to NAFL or progress to the fibrotic stage. Thus, in the ‘dynamic model’ of NAFLD, it has been conceptualized that in early NAFLD, there is dynamic cycling between NAFL and NASH[114] (Figure 3).

**Slow and rapid progressor:** In the same meta-analysis discussed above, Singh *et al*[112] also had identified significant heterogeneity among disease progression in NAFLD. They reported 2 subtypes of NAFLD patients according to fibrosis progression rate- rapid and slow progressor. The rapid progressors were around 20% of the NAFLD group who progressed rapidly from baseline (stage 0 fibrosis) to advanced (stage 3 or 4 fibrosis). On the other hand, the majority of NAFLD patients are slow progressors who only progressed 1 or 2 stage fibrosis in a similar time frame. Older age, low ASL: Alanine aminotransferase (ALT) ratio, co-morbidities like diabetes mellitus or hypertension, and genetic polymorphisms are probable risk factors for rapid progressors[103,115] (Figure 3).

**HCC:** With the progressive increase in the prevalence of NAFLD worldwide, the risk of HCC and liver-related mortality are likely to rise as a consequence. Viral hepatitis-related HCC usually occurs in the background of the advanced stage of cirrhosis. Though classically HCC usually occurs in the advanced stage of cirrhosis in the NAFLD spectrum, this is not true for all the cases of NAFLD-related HCC[116]. Rather one of the most common causes of chronic liver disease-related HCC without evidence of cirrhosis is NAFLD[5]. Leung *et al*[117] had reported 15% percent of NAFLD-related HCC as non-cirrhotic and they usually had larger hepatic tumor diameter at diagnosis. In a retrospective analysis, Mohamad *et al*[118] also reported that HCC in NAFLD patients without cirrhosis are likely to present in the older age group with a larger tumor size with a high recurrence rate in comparison to those with cirrhosis (Figure 3).

**THERAPEUTIC AND RESEARCH IMPLICATIONS**

***NAFLD progression and prognostication***

Many factors may influence the progression of NAFLD to the more advanced stage but are not routinely or easily assessed in day-to-day practice (*e.g.*, genotype, gut microbiome, mitochondrial function, immunological response)[119]. Consequently, we need to consider the natural history studies to help provide clinical, biochemical, and histological variables that can be utilized to decipher which patients will develop severe disease with worse outcomes. With regard to clinical features, a paired biopsy study by McPherson *et al*[111] underscores the impact of IR with 80% of patients with NAFL and progression of fibrosis developing diabetes by the time of follow-up biopsy compared with 25% of nonprogressors. Other studies have also shown that weight gain and worsening IR are associated with fibrosis progression in NAFLD[110]. Data for biochemical predictors are somewhat deficient. However, a study found that in patients with biopsy-proven NASH and compensated cirrhosis; lower levels of serum cholesterol, ALT, and platelets are independently associated with hepatic complications and higher aspartate aminotransferase (AST)/ALT ratio with overall mortality[120]. In NAFLD, baseline histology can provide a good prognostic value. According to a systemic review and meta-analysis of paired-biopsy studies, a third of individuals with NAFLD will have progression of fibrosis with a mean progression rate of 0.14 stages *per* annum for NASH, corresponding to one stage of fibrosis progression over a median of 7.1 years[112]. Nevertheless, many epidemiological studies have de-emphasized the presence of NASH and confirmed the presence and degree of fibrosis as the most important histologic predictor of liver-related morbidity and mortality[121,122].

It is now widely accepted that the severity of fibrosis is the only significant predictor of outcomes in NAFLD. The histological differentiation between NAFL and NASH is unlikely to predict fibrosis progression and carries very little prognostic value. Thus, it is better to consider the diagnosis of patients with advanced fibrosis (F3 and F4) because this stage is a predictor for hepatic and extrahepatic morbidity and mortality[123]. This strategy identifies those with liver disease sufficient to call for specific interventions to prevent complications of cirrhosis and the development of HCC. People with NAFL or NASH with early F0–F2 don’t need to be considered as having liver disease necessitating intervention owing to the low risk of liver-related complications. In these persons, metabolic risk factors like diabetes should be addressed to optimize CV outcomes, with likely benefits on liver disease[123]. As progressive fibrosis indicates a poor prognosis with unfavorable CV and adverse hepatic outcomes, the approach should now focus on the risk stratification of patients and identify those needing liver-specific intervention.

***Non-invasive tests of hepatic fibrosis***

As the severity of fibrosis is the major driver for the long-term prognosis of NAFLD patients, it is, therefore, critical to identify patients at higher risk of advanced fibrosis to optimize their management[124]. Although required to detect patients with NASH and early fibrosis, liver biopsy is an invasive procedure. Patient acceptability is low, and it is not desirable to perform liver biopsy repetitively to assess disease progression and response to treatment. Moreover, as only a small proportion of the patients would develop liver-related complications, performing non-invasive tests (NITs) as the primary assessment is preferable[125]. This section focuses on the confounding factors that can affect the performance and accuracy of NITs of liver fibrosis in patients with NAFLD.

***Impact of confounding factors***

Non-invasive fibrosis scores are usually used to detect or exclude advanced fibrosis in individuals with NAFLD. A few studies purposely looked at reasons for imprecise prediction by these scores. In a multicentric European study in subjects with biopsy-proven NAFLD, the AST-to-ALT ratio, NAFLD fibrosis score (NFS) and Fibrosis-4 (FIB-4) index performed poorly for the detection of significant fibrosis in persons aged 35 years or below[126]. The specificity of the FIB-4 index and NFS reduced to unacceptable levels in those aged 65 years and older in the same study. This reason is that age is a component of both the fibrosis scores. The performance of NITs and the used transient elastography (TE) liver stiffness cutoffs in different ethnic populations and special subpopulations such as individuals with diabetes and obesity also need to be taken into account. For example, depending on the ethnicity, the diagnostic accuracy of the NITs may be altered. Compared to Western populations, South Asians develop more metabolic complications at lower body mass indices. The accuracy of the NFS, AST-to-platelet ratio index, FIB-4, AST/ALT ratio, and BARD score is found to be lower in the South Asian population in comparison with the Caucasian population[127]. In addition, the NFS has a lower sensitivity in individuals of South Asian descent, as the majority had a lower BMI and were younger than Caucasian counterparts with a comparable disease stage, and therefore had a lower score[125]. Serum markers of liver fibrosis and possible confounding factors are summarized in Table 1.

With regards to imaging modalities that estimate liver stiffness as a potential surrogate of hepatic fibrosis, vibration-controlled transient elastography (VCTE) has been widely validated against liver histology[128] and shows correlation with clinical outcomes in longitudinal studies[129]. However, there are a number of factors to be considered while using this modality. Pathologies that increase liver stiffness can lead to a false-positive diagnosis of advanced fibrosis. Besides, high BMI and severe hepatic steatosis have been reported to increase the false positive rate of VCTE[130]. A recent study suggests that when using the XL probe in obese patients, steatosis does not augment liver stiffness independent of fibrosis[128]. Magnetic resonance elastography (MRE) can surmount many of these barriers, except for iron overload and acute inflammation; nonetheless, restricted availability at most centers and cost are the limiting factors. MRE has higher applicability and accuracy than VCTE when compared head-to-head[131].

While it is expected that blood-based parameters or imaging modalities will replace liver biopsy for the diagnosis in people who would benefit from treatment, equally it indicates that validation of any future marker should be done in more specifically defined cohorts. A recent International Consensus Panel suggested that the factors that shape the NAFLD heterogeneity should be taken into account when devising risk-stratification scores and algorithms[2]. Caution should be exercised by clinicians during the interpretation of test results when the tests are applied in patients with potential confounding factors.

***Considerations for best practice***

Early detection of advanced fibrosis is essential in the efforts to halt the NASH progression. Therefore, screening is vital to ensure that patients, mainly those with advanced F3–F4, are identified and linked to care before they develop end-stage liver disease. With the development of reliable NITs to identify patients with advanced fibrosis, there is now potential to put management strategies earlier in place[132]. Clinicians need to be more proactive in detecting patients with advanced fibrosis due to NASH. Figure 4 shows a diagnostic algorithm that targets screening of patients with characteristics of MetS who are at risk of progressive fibrosis. This is in accordance with guideline recommendations to screen this high-risk group[133]. This pathway includes sequential use of NITs (preferably a serum biomarker and an imaging technique) and can decrease secondary and tertiary referral rates and achieve larger cost savings.

In the Asia–Pacific region, quite a few studies have assessed the cross-sectional accuracy of non-invasive surrogates of liver biopsy among NAFLD patients[134,135]. It has been suggested that the serum tests and physical tools when used in combinations can yield more reliable data than that provided by either method alone[136]. Nevertheless, concerns are there regarding the definition of threshold values in Asian patients and Asia-Pacific Working Party stated that “at the present time, the clinical use of such tools to avoid liver biopsy remains undefined”[137].

Newsome *et al*[138] recently published the FibroScan-AST (FAST) score for the non-invasive identification of patients with significant fibrosis (≥ F2) and a NAFLD activity score (NAS) of ≥ 4 to detect those at increased risk of disease progression. This could reduce unnecessary liver biopsies in patients unlikely to have significant disease. The incorporation of VCTE values in the score enhanced the diagnostic performance. This prospective study was validated in multiple global cohorts from North America, Europe, and Asia. Discrimination was considerably higher for the FAST score when compared with FIB-4 and NFS. Now, further research on the performance of the FAST score is required to transition the use of such predictive models to clinical practice. The diagnostic accuracy of the sequential combination of FIB-4 and VCTE had been evaluated recently in an individual participant data meta-analysis that included 5735 patients. Depending upon the different cut-offs used, this combined algorithm can diagnose cirrhosis with a specificity of 95%-98%, obviating the need for liver biopsy[139].

***Identification of novel therapeutic targets***

As the burden of NAFLD has become increasingly evident, so also have hurdles to developing effective therapeutic points of action. The development of progressive steatohepatitis is connected to excess metabolic substrate delivery to the liver that, in turn, induces cell stress, which can activate inflammatory and apoptotic signaling. Eventually, inflammation triggers a fibrogenic response that can lead to cirrhosis in the end[140]. This simplified model facilitates the evaluation of precise mechanisms underlying each of these factors and targeting them for treatment. Table 2 summarizes proposed ‘druggable’ pathophysiologic targets in NAFLD[141-153].

Quite a few of the recently carried out phase 2 and 3 studies failed to reproduce the encouraging antifibrotic or NASH-resolving effects observed in animal models. Reasons for this discrepancy between preclinical models and clinical settings are likely diverse. Most importantly, no model can ever assess compounds in the actual physiological settings of heterogeneous human populations. This aspect may become further relevant if mechanisms are not entirely translatable between two different species[154]. Additionally, none of the available NASH models used for preclinical trials adequately represents all the human disease aspects from the macroscopic to the molecular level. Moreover, only a few models reflect linked extrahepatic diseases (such as atherosclerosis, obesity, or IR). Finally, a higher heterogeneity in humans in relation to genetics, the gut microbiota, gender, and existing comorbidities leads to even more complications. It is, therefore, critical to recognize the drawbacks of preclinical models to improve clinical trial outcomes in drug development.

There is significant interindividual variability in the NAFLD susceptibility and for progression to liver-related complications[49]. It is becoming more and more apparent that there is substantial heterogeneity in the molecular and cellular processes propelling the disease from one patient to the next. This understanding raises the possibility of matching specific therapeutic strategies to the particular disease drivers in a given patient. The development of such personalized approaches and the detection of subpopulations with distinctive disease drivers will need a combination of phenotypic, genetic, and molecular data[140]. Furthermore, genetic insights present a powerful approach to deduce and prioritize candidate drugs. Such selection can avoid numerous drawbacks while defining likely benefits[155]. However, drug discovery based on genetics is still in its infancy, and this area will present its challenges. NAFLD is associated with several metabolic disturbances. As many circadian clock-controlled genes are fundamental in the metabolic processes of the body, it is not unexpected that some of these genes can be potential therapeutic targets[156]. Thus, by considering the circadian cycling of their targets, new drugs for NAFLD can be administered in a way that optimizes the benefits and minimizes the side effects.

***Impact on clinical trials and endpoints***

Given the rising disease burden associated with NAFLD, the development of outcome measures to assess the at-risk population and validate clinically relevant study endpoints is vital. Nevertheless, the natural history of NAFLD is highly variable, often nonlinear in progression. In addition, NAFLD itself is a heterogeneous disease that is shaped by the dynamic interaction between genetic predisposition, environmental factors, and several modifiable risk factors[157]. This pathogenetic background provides numerous potential targets for therapeutic intervention, however, this same complexity limits defining clear, measurable, and objective clinical endpoints[158]. Considering these factors, surrogate endpoints, which can be used to predict outcomes on clinically relevant endpoints, are expected to be beneficial in most patients. Furthermore, NAFLD is a slowly progressive disease, with a gap of many years between onset and development of “hard” clinical outcomes, such as liver-related and all-cause mortality. As stated earlier, the fibrosis stage is the most important predictor of liver-related outcomes. Unfortunately, the progression of fibrosis itself is also slow, with a median of 7.1 years in subjects with NASH[112]. Thus, selecting meaningful clinical endpoints has been a major challenge in drug development and validation. At present, before enrolling patients into NASH clinical trials, identifying which patients with NAFLD have NASH, particularly those with advanced fibrosis, is one of the major stumbling blocks. Once these at-risk patients have been selected, monitoring for fibrosis regression in individuals with advanced fibrosis appears to be the optimal endpoint in clinical trials and should supplant NASH-based endpoints[158]. Surrogate measures of liver-related outcomes also seem reliable. Although important, to assess for all-cause mortality (primarily CV death) and liver-related mortality will require longer-term follow-up.

Liver biopsy is essentially prone to sampling error and interobserver variability; its invasive nature also makes it a barrier for large clinical trials. Given these limitations, the development of accurate, robust, and reproducible noninvasive surrogate endpoints which may ultimately replace biopsy in trials are eagerly sought in NAFLD research[159]. Algorithms such as NFS and FIB-4 may be useful tools for prescreening, in order to enrich the patient group with an appropriate spectrum of NASH and fibrosis for enrollment. Noninvasive imaging methods such as VCTE and MRE are likely to play a future role but presently lack the ability to differentiate between closely related fibrosis stages[160].

To summarize, a combination of the slow nature of disease progression in NAFLD, heterogeneity of therapeutic targets, and inherent limitations of serial liver biopsy to evaluate effects of intervention have considerably hampered clinical trial design as well as the development of new and effective therapies[158]. Thus, the standard trial design that does not consider the disease heterogeneity may not be the best approach for learning this complex disease. Future clinical trials need to target patients with specific characteristics (gender, hormonal status, genetic susceptibility, metabolic and microbiota signatures, and the presence or absence of comorbidities) once the connections between these characteristics and the therapeutic targets are clearly understood[2].

**FUTURE PERSPECTIVES**

With increasing recognition of heterogeneous molecular and genetic drivers of NAFLD, there is a possibility of precision medicine based on the identification of specific drivers of the disease. An integrated model of NAFLD development based on genetic, molecular, histology, “omics” based data (transcriptome, metabolite, proteome, microbiome), and disease phenotype to identify disease subpopulations is required for such personalized approaches[140]. Critical data on molecular heterogeneity and its relation to clinical outcomes of NAFLD to going to explore new horizons in the management of this global pandemic[161]. A better understanding of bidirectional and dynamic disease progression and regression (*e.g.* fibrosis), the influence of behavioral factors, and establishing a correlation with end-organ damage is warranted. Prospective follow-up data on the evolution of pediatric NAFLD into adulthood shall shed light on pediatric disease evolution[162]. Identification and validation of non-invasive methods of disease assessment and biomarkers will accelerate the development of pharmacotherapy and testing of combination therapies. Seamless phase II-IV trial designs, virtual placebo cohort analysis, master clinical trials testing multiple agents and multiple disease types, use of effectiveness trials in real-world settings, and patient-reported outcomes would revolutionize clinical trials for NAFLD. Precise terminology, characterization of disease heterogeneity (both molecular and clinical), novel translational models to identify new therapeutic target, and thus better designed clinical trials would help reduce the burden of the disease[2].

**CONCLUSION**

The impact of the upsurge in NAFLD patients and a rising proportion with advanced disease will be reflected in higher rates of hepatic and extrahepatic morbidity and mortality, which will continue to burden the health care system heavily. On the other hand, a lack of enough consideration of heterogeneity in risk profiles and responsiveness to treatment posing impediments that hampers progress to effective treatments. It is anticipated that a more robust understanding of pathophysiology will result in better characterization and subphenotyping of the disease and its drivers. In turn, this understanding of disease variability may help the introduction of appropriate noninvasive biomarkers for each subtype, thus promoting more individualized interventions. In this regard, any discussions on the update of nomenclature or more appropriate terminology are in the right direction. However, the proposed redefining of the disease should increase the prioritization of research activity on NAFLD to fill current knowledge gaps and find new tools to overcome the challenges. It appears to be important to place NAFLD/MAFLD/DAFLD under the same umbrella with significant comorbidities and approach NAFLD/MAFLD/DAFLD holistically rather than facing NAFLD as a separate entity. Future studies are likely to provide us the necessary prerequisites for designing more appropriate clinical trials to identify finely tailored diagnostic and treatment strategies for our patients.

**REFERENCES**

1 **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438 [PMID: 7382552]

2 **Eslam M**, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: 32044314 DOI: 10.1053/j.gastro.2019.11.312]

3 **Singh SP**, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. Non-alcoholic fatty liver disease: Not time for an obituary just yet!.*J Hepatol* 2021; **74**: 972-974 [PMID: 33340575 DOI: 10.1016/j.jhep.2020.10.015]

4 **Yki-Järvinen H**, Luukkonen PK. Heterogeneity of non-alcoholic fatty liver disease.*Liver Int* 2015; **35**: 2498-2500 [PMID: 26386359 DOI: 10.1111/liv.12970]

5 **Mittal S**, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol* 2016; **14**: 124-31.e1 [PMID: 26196445 DOI: 10.1016/j.cgh.2015.07.019]

6 **Friedman SL**, Neuschwander-Tetri BA, Rinella M, Sanyal AJ.Mechanisms of NAFLD development and therapeutic strategies.*Nat Med* 2018; **24**: 908-922 [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9]

7 **Åberg F**, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. *Hepatology* 2018; **67**: 2141-2149 [PMID: 29164643 DOI: 10.1002/hep.29631]

8 **Shiha G**, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. *Lancet Gastroenterol Hepatol* 2021; **6**: 57-64 [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2]

9 **Yuan J**, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W, Li B, Li H, Lin W, Tian C, Zhao J, Han J, An D, Zhang Q, Wei H, Zheng M, Ma X, Li W, Chen X, Zhang Z, Zeng H, Ying S, Wu J, Yang R, Liu D. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. *Cell Metab* 2019; **30**: 675-688.e7 [PMID: 31543403 DOI: 10.1016/j.cmet.2019.08.018]

10 **Jepsen P**, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sørensen HT. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. *Hepatogastroenterology* 2003; **50**: 2101-2104 [PMID: 14696473]

11 **Loria P**, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? *Dig Dis* 2005; **23**: 72-82 [PMID: 15920328 DOI: 10.1159/000084728]

12 **Polyzos SA**, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). *Metabolism* 2020; **111S**: 154318 [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318]

13 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

14 **Lin S**, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int* 2020; **40**: 2082-2089 [PMID: 32478487 DOI: 10.1111/liv.14548]

15 **Younossi ZM**, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. *Hepatology* 2021; **73**: 1194-1198 [PMID: 32544255 DOI: 10.1002/hep.31420]

16 **Dongiovanni P**, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. *Eur J Clin Invest* 2021; **51**: e13519 [PMID: 33583033 DOI: 10.1111/eci.13519]

17 **Cai J**, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. *Circ Res* 2020; **126**: 679-704 [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337]

18 **Targher G**, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. *Diabetes Metab* 2021; **47**: 101215 [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215]

19 **Shroff H**, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. *Curr Hepatol Rep* 2020; **19**: 315-326 [PMID: 33585157 DOI: 10.1007/s11901-020-00530-0]

20 **Frith J**, Day CP, Henderson E, Burt AD, Newton JL.Non-alcoholic fatty liver disease in older people.*Gerontology* 2009; **55**: 607-613 [PMID: 19690397 DOI: 10.1159/000235677]

21 **Frith J**, Jones D, Newton JL.Chronic liver disease in an ageing population.*Age Ageing* 2009; **38**: 11-18 [PMID: 19029099 DOI: 10.1093/ageing/afn242]

22 **Donati B**, Valenti L. Telomeres, NAFLD and Chronic Liver Disease.*Int J Mol Sci* 2016; **17**: 383 [PMID: 26999107 DOI: 10.3390/ijms17030383]

23 **Kuk JL**, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution.*Ageing Res Rev* 2009; **8**: 339-348 [PMID: 19576300 DOI: 10.1016/j.arr.2009.06.001]

24 **Lonardo A**, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. *Hepatology* 2019; **70**: 1457-1469 [PMID: 30924946 DOI: 10.1002/hep.30626]

25 **Lovejoy JC**, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. *Int J Obes (Lond)* 2008; **32**: 949-958 [PMID: 18332882 DOI: 10.1038/ijo.2008.25]

26 **Kurt Z**, Barrere-Cain R, LaGuardia J, Mehrabian M, Pan C, Hui ST, Norheim F, Zhou Z, Hasin Y, Lusis AJ, Yang X. Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. *Biol Sex Differ* 2018; **9**: 46 [PMID: 30343673 DOI: 10.1186/s13293-018-0205-7]

27 **Cvitanović Tomaš T**, Urlep Ž, Moškon M, Mraz M, Rozman D. *LiverSex* Computational Model: Sexual Aspects in Hepatic Metabolism and Abnormalities. *Front Physiol* 2018; **9**: 360 [PMID: 29706895 DOI: 10.3389/fphys.2018.00360]

28 **Yang JD**, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. *Hepatology* 2014; **59**: 1406-1414 [PMID: 24123276 DOI: 10.1002/hep.26761]

29 **Klair JS**, Yang JD, Abdelmalek MF, Guy CD, Gill RM, Yates K, Unalp-Arida A, Lavine JE, Clark JM, Diehl AM, Suzuki A; Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. *Hepatology* 2016; **64**: 85-91 [PMID: 26919573 DOI: 10.1002/hep.28514]

30 **Rich NE**, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, Mayo H, Singal AG. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018; **16**: 198-210.e2 [PMID: 28970148 DOI: 10.1016/j.cgh.2017.09.041]

31 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

32 **Mohanty SR**, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. *J Hepatol* 2009; **50**: 797-804 [PMID: 19231016 DOI: 10.1016/j.jhep.2008.11.017]

33 **Tabibian JH**, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? *J Gastroenterol Hepatol* 2011; **26**: 501-509 [PMID: 21332546 DOI: 10.1111/j.1440-1746.2010.06443.x]

34 **Shen J**, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, Chim AM, Chan AW, Choi PC, Woo J, Chu WC, Wong VW. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. *Aliment Pharmacol Ther* 2014; **39**: 532-539 [PMID: 24417250 DOI: 10.1111/apt.12609]

35 **Trovato FM**, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. *Clin Nutr* 2015; **34**: 86-88 [PMID: 24529325 DOI: 10.1016/j.clnu.2014.01.018]

36 **David LA**, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014; **505**: 559-563 [PMID: 24336217 DOI: 10.1038/nature12820]

37 **Loomba R**, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab* 2017; **25**: 1054-1062.e5 [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001]

38 **Ilan Y**. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. *World J Gastroenterol* 2012; **18**: 2609-2618 [PMID: 22690069 DOI: 10.3748/wjg.v18.i21.2609]

39 **Jialal I**, Kaur H, Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. *J Clin Endocrinol Metab* 2014; **99**: 39-48 [PMID: 24187406 DOI: 10.1210/jc.2013-3092]

40 **Hall AB**, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease.*Nat Rev Genet* 2017; **18**: 690-699 [PMID: 28824167 DOI: 10.1038/nrg.2017.63]

41 **Brooks AW**, Priya S, Blekhman R, Bordenstein SR. Gut microbiota diversity across ethnicities in the United States. *PLoS Biol* 2018; **16**: e2006842 [PMID: 30513082 DOI: 10.1371/journal.pbio.2006842]

42 **Loos RJF**, Kilpeläinen TO. Genes that make you fat, but keep you healthy. *J Intern Med* 2018; **284**: 450-463 [PMID: 30144199 DOI: 10.1111/joim.12827]

43 **Eckel N**, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. *Lancet Diabetes Endocrinol* 2018; **6**: 714-724 [PMID: 29859908 DOI: 10.1016/S2213-8587(18)30137-2]

44 **Agbim U**, Carr RM, Pickett-Blakely O, Dagogo-Jack S. Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. *Curr Obes Rep* 2019; **8**: 243-254 [PMID: 31144261 DOI: 10.1007/s13679-019-00349-x]

45 **Ding C**, Chan Z, Magkos F. Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype. *Curr Opin Clin Nutr Metab Care* 2016; **19**: 408-417 [PMID: 27552473 DOI: 10.1097/MCO.0000000000000317]

46 **Chen F**, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. *Hepatology* 2020; **71**: 1213-1227 [PMID: 31442319 DOI: 10.1002/hep.30908]

47 **Park JH**, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, Hwang KB, Lee IH, Kim JI, Kong SW. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. *Liver Int* 2015; **35**: 2537-2546 [PMID: 26148225 DOI: 10.1111/liv.12909]

48 **Hoang SA**, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. *Sci Rep* 2019; **9**: 12541 [PMID: 31467298 DOI: 10.1038/s41598-019-48746-5]

49 **Eslam M**, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. *J Hepatol* 2018; **68**: 268-279 [PMID: 29122391 DOI: 10.1016/j.jhep.2017.09.003]

50 **Liu YL**, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun* 2014; **5**: 4309 [PMID: 24978903 DOI: 10.1038/ncomms5309]

51 **Diogo D**, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, Vangjeli C, Weale ME, Mattsson H, Kilpeläinen E, Sleiman PMA, Reilly DF, McElwee J, Maranville JC, Chatterjee AK, Bhandari A, Nguyen KH, Estrada K, Reeve MP, Hutz J, Bing N, John S, MacArthur DG, Salomaa V, Ripatti S, Hakonarson H, Daly MJ, Palotie A, Hinds DA, Donnelly P, Fox CS, Day-Williams AG, Plenge RM, Runz H. Phenome-wide association studies across large population cohorts support drug target validation. *Nat Commun* 2018; **9**: 4285 [PMID: 30327483 DOI: 10.1038/s41467-018-06540-3]

52 **Mahajan A**, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, Gan W, Kitajima H, Taliun D, Rayner NW, Guo X, Lu Y, Li M, Jensen RA, Hu Y, Huo S, Lohman KK, Zhang W, Cook JP, Prins BP, Flannick J, Grarup N, Trubetskoy VV, Kravic J, Kim YJ, Rybin DV, Yaghootkar H, Müller-Nurasyid M, Meidtner K, Li-Gao R, Varga TV, Marten J, Li J, Smith AV, An P, Ligthart S, Gustafsson S, Malerba G, Demirkan A, Tajes JF, Steinthorsdottir V, Wuttke M, Lecoeur C, Preuss M, Bielak LF, Graff M, Highland HM, Justice AE, Liu DJ, Marouli E, Peloso GM, Warren HR; ExomeBP Consortium; MAGIC Consortium; GIANT Consortium, Afaq S, Afzal S, Ahlqvist E, Almgren P, Amin N, Bang LB, Bertoni AG, Bombieri C, Bork-Jensen J, Brandslund I, Brody JA, Burtt NP, Canouil M, Chen YI, Cho YS, Christensen C, Eastwood SV, Eckardt KU, Fischer K, Gambaro G, Giedraitis V, Grove ML, de Haan HG, Hackinger S, Hai Y, Han S, Tybjærg-Hansen A, Hivert MF, Isomaa B, Jäger S, Jørgensen ME, Jørgensen T, Käräjämäki A, Kim BJ, Kim SS, Koistinen HA, Kovacs P, Kriebel J, Kronenberg F, Läll K, Lange LA, Lee JJ, Lehne B, Li H, Lin KH, Linneberg A, Liu CT, Liu J, Loh M, Mägi R, Mamakou V, McKean-Cowdin R, Nadkarni G, Neville M, Nielsen SF, Ntalla I, Peyser PA, Rathmann W, Rice K, Rich SS, Rode L, Rolandsson O, Schönherr S, Selvin E, Small KS, Stančáková A, Surendran P, Taylor KD, Teslovich TM, Thorand B, Thorleifsson G, Tin A, Tönjes A, Varbo A, Witte DR, Wood AR, Yajnik P, Yao J, Yengo L, Young R, Amouyel P, Boeing H, Boerwinkle E, Bottinger EP, Chowdhury R, Collins FS, Dedoussis G, Dehghan A, Deloukas P, Ferrario MM, Ferrières J, Florez JC, Frossard P, Gudnason V, Harris TB, Heckbert SR, Howson JMM, Ingelsson M, Kathiresan S, Kee F, Kuusisto J, Langenberg C, Launer LJ, Lindgren CM, Männistö S, Meitinger T, Melander O, Mohlke KL, Moitry M, Morris AD, Murray AD, de Mutsert R, Orho-Melander M, Owen KR, Perola M, Peters A, Province MA, Rasheed A, Ridker PM, Rivadineira F, Rosendaal FR, Rosengren AH, Salomaa V, Sheu WH, Sladek R, Smith BH, Strauch K, Uitterlinden AG, Varma R, Willer CJ, Blüher M, Butterworth AS, Chambers JC, Chasman DI, Danesh J, van Duijn C, Dupuis J, Franco OH, Franks PW, Froguel P, Grallert H, Groop L, Han BG, Hansen T, Hattersley AT, Hayward C, Ingelsson E, Kardia SLR, Karpe F, Kooner JS, Köttgen A, Kuulasmaa K, Laakso M, Lin X, Lind L, Liu Y, Loos RJF, Marchini J, Metspalu A, Mook-Kanamori D, Nordestgaard BG, Palmer CNA, Pankow JS, Pedersen O, Psaty BM, Rauramaa R, Sattar N, Schulze MB, Soranzo N, Spector TD, Stefansson K, Stumvoll M, Thorsteinsdottir U, Tuomi T, Tuomilehto J, Wareham NJ, Wilson JG, Zeggini E, Scott RA, Barroso I, Frayling TM, Goodarzi MO, Meigs JB, Boehnke M, Saleheen D, Morris AP, Rotter JI, McCarthy MI. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat Genet* 2018; **50**: 559-571 [PMID: 29632382 DOI: 10.1038/s41588-018-0084-1]

53 **Simons N**, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers MCGJ. PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease.*Gastroenterology* 2017; **152**: 912-913 [PMID: 28157516 DOI: 10.1053/j.gastro.2016.12.020]

54 **Abul-Husn NS**, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.*N Engl J Med* 2018; **378**: 1096-1106 [PMID: 29562163 DOI: 10.1056/NEJMoa1712191]

55 **Pirola CJ**, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. *Gut* 2015; **64**: 800-812 [PMID: 24973316 DOI: 10.1136/gutjnl-2014-306996]

56 **Sookoian S**, Rohr C, Salatino A, Dopazo H, Fernandez Gianotti T, Castaño GO, Pirola CJ. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.*Oncotarget* 2017; **8**: 22917-22926 [PMID: 28206970 DOI: 10.18632/oncotarget.15286]

57 **Ahrens M**, Ammerpohl O, von Schönfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, Erhart W, Egberts J, Sipos B, Schreiber S, Häsler R, Stickel F, Becker T, Krawczak M, Röcken C, Siebert R, Schafmayer C, Hampe J. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. *Cell Metab* 2013; **18**: 296-302 [PMID: 23931760 DOI: 10.1016/j.cmet.2013.07.004]

58 **Hardy T**, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, Henderson E, Tiniakos D, White S, French J, Mann DA, Anstee QM, Mann J. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. *Gut* 2017; **66**: 1321-1328 [PMID: 27002005 DOI: 10.1136/gutjnl-2016-311526]

59 **Kitamoto T**, Kitamoto A, Ogawa Y, Honda Y, Imajo K, Saito S, Yoneda M, Nakamura T, Nakajima A, Hotta K. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. *J Hepatol* 2015; **63**: 494-502 [PMID: 25776890 DOI: 10.1016/j.jhep.2015.02.049]

60 **Baker PR 2nd**, Friedman JE. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.*J Clin Invest* 2018; **128**: 3692-3703 [PMID: 30168806 DOI: 10.1172/JCI120846]

61 **Suter MA**, Ma J, Vuguin PM, Hartil K, Fiallo A, Harris RA, Charron MJ, Aagaard KM. In utero exposure to a maternal high-fat diet alters the epigenetic histone code in a murine model. *Am J Obstet Gynecol* 2014; **210**: 463.e1-463.e11 [PMID: 24793723 DOI: 10.1016/j.ajog.2014.01.045]

62 **Gemma C**, Sookoian S, Alvariñas J, García SI, Quintana L, Kanevsky D, González CD, Pirola CJ. Maternal pregestational BMI is associated with methylation of the PPARGC1A promoter in newborns. *Obesity (Silver Spring)* 2009; **17**: 1032-1039 [PMID: 19148128 DOI: 10.1038/oby.2008.605]

63 **Struben VM**, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.*Am J Med* 2000; **108**: 9-13 [PMID: 11059435 DOI: 10.1016/s0002-9343(99)00315-0]

64 **Caussy C**, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R; Familial NAFLD Cirrhosis Research Consortium. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. *J Clin Invest* 2017; **127**: 2697-2704 [PMID: 28628033 DOI: 10.1172/JCI93465]

65 **Boyle M**, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. *J Hepatol* 2018; **68**: 251-267 [PMID: 29113910 DOI: 10.1016/j.jhep.2017.11.006]

66 **Rehm J**, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. *Drug Alcohol Rev* 2010; **29**: 437-445 [PMID: 20636661 DOI: 10.1111/j.1465-3362.2009.00153.x]

67 **Mato JM**, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; **25**: 3009-3020 [PMID: 31293337 DOI: 10.3748/wjg.v25.i24.3009]

68 **Vandromme M**, Jun T, Perumalswami P, Dudley JT, Branch A, Li L. Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. *Pac Symp Biocomput* 2020; **25**: 91-102 [PMID: 31797589]

69 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

70 **Li J**, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2019; **4**: 389-398 [PMID: 30902670 DOI: 10.1016/S2468-1253(19)30039-1]

71 **Fan JG**, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia.*J Hepatol* 2017; **67**: 862-873 [PMID: 28642059 DOI: 10.1016/j.jhep.2017.06.003]

72 **Mohan V**, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. *Diabetes Res Clin Pract* 2009; **84**: 84-91 [PMID: 19168251 DOI: 10.1016/j.diabres.2008.11.039]

73 **Lin YC**, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. *J Pediatr* 2011; **158**: 740-744 [PMID: 21168155 DOI: 10.1016/j.jpeds.2010.11.016]

74 **Bhatt SP**, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA.Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease.*Metab Syndr Relat Disord* 2013; **11**: 329-335 [PMID: 23734760 DOI: 10.1089/met.2012.0064]

75 **Zain SM**, Mohamed Z, Mahadeva S, Rampal S, Basu RC, Cheah PL, Salim A, Mohamed R. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. *PLoS One* 2013; **8**: e58538 [PMID: 23484035 DOI: 10.1371/journal.pone.0058538]

76 **Yang Z**, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. *Mol Biol Rep* 2011; **38**: 1145-1150 [PMID: 20625834 DOI: 10.1007/s11033-010-0212-1]

77 **Cai W**, Weng DH, Yan P, Lin YT, Dong ZH, Mailamuguli, Yao H. Genetic polymorphisms associated with nonalcoholic fatty liver disease in Uyghur population: a case-control study and meta-analysis. *Lipids Health Dis* 2019; **18**: 14 [PMID: 30646922 DOI: 10.1186/s12944-018-0877-3]

78 **Zhai HL**, Wang NJ, Han B, Li Q, Chen Y, Zhu CF, Chen YC, Xia FZ, Cang Z, Zhu CX, Lu M, Lu YL. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). *Br J Nutr* 2016; **115**: 1352-1359 [PMID: 26888280 DOI: 10.1017/S0007114516000386]

79 **Lim S**, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, Kim KW, Lim JY, Park KS, Jang HC. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). *Diabetes Care* 2010; **33**: 1652-1654 [PMID: 20460442 DOI: 10.2337/dc10-0107]

80 **Kawamura Y**, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. *Am J Gastroenterol* 2012; **107**: 253-261 [PMID: 22008893 DOI: 10.1038/ajg.2011.327]

81 **Michitaka K**, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. *J Gastroenterol* 2010; **45**: 86-94 [PMID: 19789837 DOI: 10.1007/s00535-009-0128-5]

82 **Wong SW**, Chan WK. Epidemiology of non-alcoholic fatty liver disease in Asia.*Indian J Gastroenterol* 2020; **39**: 1-8 [PMID: 32152903 DOI: 10.1007/s12664-020-01018-x]

83 **Alazawi W**, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR. Ethnicity and the diagnosis gap in liver disease: a population-based study. *Br J Gen Pract* 2014; **64**: e694-e702 [PMID: 25348993 DOI: 10.3399/bjgp14X682273]

84 **Soleimani D**, Ranjbar G, Rezvani R, Goshayeshi L, Razmpour F, Nematy M. Dietary patterns in relation to hepatic fibrosis among patients with nonalcoholic fatty liver disease. *Diabetes Metab Syndr Obes* 2019; **12**: 315-324 [PMID: 30881075 DOI: 10.2147/DMSO.S198744]

85 **Huang Y**, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. *J Biol Chem* 2011; **286**: 37085-37093 [PMID: 21878620 DOI: 10.1074/jbc.M111.290114]

86 **Kawaguchi T**, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012; **7**: e38322 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]

87 **Zain SM**, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu RC, Mohamed Z. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.*Hum Genet* 2012; **131**: 1145-1152 [PMID: 22258181 DOI: 10.1007/s00439-012-1141-y]

88 **Kozlitina J**, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2014; **46**: 352-356 [PMID: 24531328 DOI: 10.1038/ng.2901]

89 **Goffredo M**, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, Savoye M, Zhao H, Bale AE, Santoro N. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. *Hepatology* 2016; **63**: 117-125 [PMID: 26457389 DOI: 10.1002/hep.28283]

90 **Anderson EL**, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. *PLoS One* 2015; **10**: e0140908 [PMID: 26512983 DOI: 10.1371/journal.pone.0140908]

91 **Brumbaugh DE**, Tearse P, Cree-Green M, Fenton LZ, Brown M, Scherzinger A, Reynolds R, Alston M, Hoffman C, Pan Z, Friedman JE, Barbour LA. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. *J Pediatr* 2013; **162**: 930-6.e1 [PMID: 23260099 DOI: 10.1016/j.jpeds.2012.11.017]

92 **Modi N**, Murgasova D, Ruager-Martin R, Thomas EL, Hyde MJ, Gale C, Santhakumaran S, Doré CJ, Alavi A, Bell JD. The influence of maternal body mass index on infant adiposity and hepatic lipid content.*Pediatr Res* 2011; **70**: 287-291 [PMID: 21629154 DOI: 10.1203/PDR.0b013e318225f9b1]

93 **Oddy WH**, Herbison CE, Jacoby P, Ambrosini GL, O'Sullivan TA, Ayonrinde OT, Olynyk JK, Black LJ, Beilin LJ, Mori TA, Hands BP, Adams LA. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. *Am J Gastroenterol* 2013; **108**: 778-785 [PMID: 23545714 DOI: 10.1038/ajg.2013.95]

94 **Ayonrinde OT**, Oddy WH, Adams LA, Mori TA, Beilin LJ, de Klerk N, Olynyk JK. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. *J Hepatol* 2017; **67**: 568-576 [PMID: 28619255 DOI: 10.1016/j.jhep.2017.03.029]

95 **Molleston JP**, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.*J Pediatr* 2014; **164**: 707-713.e3 [PMID: 24360992 DOI: 10.1016/j.jpeds.2013.10.071]

96 **Schwimmer JB**, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease.*Hepatology* 2005; **42**: 641-649 [PMID: 16116629 DOI: 10.1002/hep.20842]

97 **Goyal NP**, Schwimmer JB.The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease.*Clin Liver Dis* 2016; **20**: 325-338 [PMID: 27063272 DOI: 10.1016/j.cld.2015.10.003]

98 **Nobili V**, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. *Hepatology* 2006; **44**: 458-465 [PMID: 16871574 DOI: 10.1002/hep.21262]

99 **Ye Q**, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 739-752 [PMID: 32413340 DOI: 10.1016/S2468-1253(20)30077-7]

100 **Lu FB**, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2020; **35**: 2041-2050 [PMID: 32573017 DOI: 10.1111/jgh.15156]

101 **Shi Y**, Wang Q, Sun Y, Zhao X, Kong Y, Ou X, Jia J, Wu S, You H. The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2020; **54**: 378-387 [PMID: 31651571 DOI: 10.1097/MCG.0000000000001270]

102 **Honda Y**, Yoneda M, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Mawatari H, Fujita K, Hyogo H, Ueno T, Chayama K, Saito S, Nakajima A, Hotta K. Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors. *Hepatol Res* 2016; **46**: 1011-1018 [PMID: 26763865 DOI: 10.1111/hepr.12648]

103 **Adams LA**, Marsh JA, Ayonrinde OT, Olynyk JK, Ang WQ, Beilin LJ, Mori T, Palmer LJ, Oddy WW, Lye SJ, Pennell CE. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. *J Gastroenterol Hepatol* 2012; **27**: 1520-1527 [PMID: 22414273 DOI: 10.1111/j.1440-1746.2012.07120.x]

104 **Eslam M**, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.*Nat Commun* 2015; **6**: 6422 [PMID: 25740255 DOI: 10.1038/ncomms7422]

105 **Yun Y,** Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. *PLoS One* 2019; **14:** e0213692 [DOI: 10.1371/journal.pone.0213692]

106 **Feldman A**, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, Huber-Schönauer U, Niederseer D, Stickel F, Auer S, Haschke-Becher E, Patsch W, Datz C, Aigner E. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. *Am J Gastroenterol* 2017; **112**: 102-110 [PMID: 27527746 DOI: 10.1038/ajg.2016.318]

107 **Eslam M**, Chen F, George J. NAFLD in Lean Asians. *Clin Liver Dis (Hoboken)* 2020; **16**: 240-243 [PMID: 33489095 DOI: 10.1002/cld.930]

108 **Hagström H**, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. *Hepatol Commun* 2018; **2**: 48-57 [PMID: 29404512 DOI: 10.1002/hep4.1124]

109 **Wang AY**, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease.*Clin Nutr* 2019; **38**: 975-981 [PMID: 30466956 DOI: 10.1016/j.clnu.2018.08.008]

110 **Pais R**, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. *J Hepatol* 2013; **59**: 550-556 [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027]

111 **McPherson S**, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. *J Hepatol* 2015; **62**: 1148-1155 [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034]

112 **Singh S**, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 2015; **13**: 643-54.e1-9; quiz e39-40 [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014]

113 **Musso G**, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011; **43**: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]

114 **De A**, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.*J Clin Exp Hepatol* 2020; **10**: 255-262 [PMID: 32405182 DOI: 10.1016/j.jceh.2019.09.005]

115 **Kechagias S**, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. *Metabolism* 2020; **111S**: 154183 [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183]

116 **Anastasopoulos NT**, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma.*Expert Rev Gastroenterol Hepatol* 2020; **14**: 1025-1033 [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244]

117 **Leung C**, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.*World J Gastroenterol* 2015; **21**: 1189-1196 [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189]

118 **Mohamad B**, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. *Hepatol Int* 2016; **10**: 632-639 [PMID: 26558795 DOI: 10.1007/s12072-015-9679-0]

119 **Marjot T**, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. *Endocr Rev* 2020; **41** [PMID: 31629366 DOI: 10.1210/endrev/bnz009]

120 **Bhala N**, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011; **54**: 1208-1216 [PMID: 21688282 DOI: 10.1002/hep.24491]

121 **Ekstedt M**, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015; **61**: 1547-1554 [PMID: 25125077 DOI: 10.1002/hep.27368]

122 **Hagström H**, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. *J Hepatol* 2017; **67**: 1265-1273 [PMID: 28803953 DOI: 10.1016/j.jhep.2017.07.027]

123 **Rowe IA**, Parker R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 449-450 [PMID: 31197261 DOI: 10.1038/s41575-019-0168-0]

124 **Vilar-Gomez E**, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. *J Hepatol* 2018; **68**: 305-315 [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013]

125 **Wai JW**, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease.*J Gastroenterol* 2020; **55**: 731-741 [PMID: 32451628 DOI: 10.1007/s00535-020-01686-8]

126 **McPherson S**, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.*Am J Gastroenterol* 2017; **112**: 740-751 [PMID: 27725647 DOI: 10.1038/ajg.2016.453]

127 **De Silva S**, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. *Frontline Gastroenterol* 2018; **9**: 115-121 [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865]

128 **Xia B**, Wang F, Friedrich-Rust M, Zhou F, Zhu J, Yang H, Ruan W, Zeng Z. Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis. *Medicine (Baltimore)* 2018; **97**: e11816 [PMID: 30278481 DOI: 10.1097/MD.0000000000011816]

129 **Shili-Masmoudi S**, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. *Liver Int* 2020; **40**: 581-589 [PMID: 31749300 DOI: 10.1111/liv.14301]

130 **Petta S**, Maida M, Macaluso FS, Di Marco V, Cammà C, Cabibi D, Craxì A. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. *Hepatology* 2015; **62**: 1101-1110 [PMID: 25991038 DOI: 10.1002/hep.27844]

131 **Park CC**, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner D, Sirlin CB, Loomba R. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2017; **152**: 598-607.e2 [PMID: 27911262 DOI: 10.1053/j.gastro.2016.10.026]

132 **Augustin S**, Ahmed A, Alkhouri N, Canbay A, Corless L, Nakajima A, Okanoue T, Petta S, Ratziu V, Tsochatzis EA, Wong VW, Romero-Gómez M. Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. *J Gastrointestin Liver Dis* 2020; **29**: 235-245 [PMID: 32530991 DOI: 10.15403/jgld-775]

133 European Association for the Study of the Liver (EASL).; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64:** 1388-1402 [DOI: 10.1159/000443344]

134 **Sumida Y**, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.*BMC Gastroenterol* 2012; **12**: 2 [PMID: 22221544 DOI: 10.1186/1471-230X-12-2]

135 **Yu SJ**, Kim DH, Lee JH, Chung GE, Yim JY, Park MJ, Kim YJ, Yoon JH, Jang JJ, Lee HS. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease.*Korean J Gastroenterol* 2011; **57**: 19-27 [PMID: 21258197 DOI: 10.4166/kjg.2011.57.1.19]

136 **Wong GL**, Chan HL. Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. *Hepatol Int* 2015; **9**: 481-483 [PMID: 25788206 DOI: 10.1007/s12072-015-9625-1]

137 **Wong VW**, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. *J Gastroenterol Hepatol* 2018; **33**: 70-85 [PMID: 28670712 DOI: 10.1111/jgh.13857]

138 **Newsome PN**, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol* 2020; **5**: 362-373 [PMID: 32027858 DOI: 10.1016/S2468-1253(19)30383-8]

139 **Mózes FE**, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut* 2021 [PMID: 34001645 DOI: 10.1136/gutjnl-2021-324243]

140 **Sanyal AJ**.Past, present and future perspectives in nonalcoholic fatty liver disease.*Nat Rev Gastroenterol Hepatol* 2019; **16**: 377-386 [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8]

141 **Younossi ZM**, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019; **394**: 2184-2196 [PMID: 31813633 DOI: 10.1016/S0140-6736(19)33041-7]

142 **Patel K**, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. *Hepatology* 2020; **72**: 58-71 [PMID: 32115759 DOI: 10.1002/hep.31205]

143 **Gawrieh S,** Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. *Hepatology* 2021 [DOI: 10.1002/hep.31843]

144 **Amin N,** Carvajal-Gonzalez S, Aggarwal N,Tuthill T, Inglot M, Bergman A, Esler W. Abstract 31: PF-05221304 (PF’1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT: phase 2a, dose-ranging study. *Hepatology* 2019; **70:** 21A-22A [DOI: 10.1016/s0168-8278(20)31392-1]

145 **Armstrong MJ**, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016; **387**: 679-690 [PMID: 26608256 DOI: 10.1016/S0140-6736(15)00803-X]

146 **Petit JM**, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. *J Clin Endocrinol Metab* 2017; **102**: 407-415 [PMID: 27732328 DOI: 10.1210/jc.2016-2775]

147 **Eguchi Y**, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). *Hepatol Res* 2015; **45**: 269-278 [PMID: 24796231 DOI: 10.1111/hepr.12351]

148 **Newsome PN**, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.*N Engl J Med* 2021; **384**: 1113-1124 [PMID: 33185364 DOI: 10.1056/NEJMoa2028395]

149 **Harrison SA**, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. *J Hepatol* 2020; **72**: 613-626 [PMID: 31697972 DOI: 10.1016/j.jhep.2019.10.023]

150 **Sanyal AJ**, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.*N Engl J Med* 2010; **362**: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

151 **Harrison SA**, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.*J Hepatol* 2020; **72**: 816-827 [PMID: 31887369 DOI: 10.1016/j.jhep.2019.11.024]

152 **Harrison SA**, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ; GS-US-321-0105 and GS-US-321-0106 Investigators. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. *Gastroenterology* 2018; **155**: 1140-1153 [PMID: 29990488 DOI: 10.1053/j.gastro.2018.07.006]

153 **Harrison SA**, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. *Gastroenterology* 2021; **160**: 219-231.e1 [PMID: 32781086 DOI: 10.1053/j.gastro.2020.08.004]

154 **Reimer KC**, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. *Hepatol Int* 2020; **14**: 8-23 [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4]

155 **Eslam M**, George J. Genetic Insights for Drug Development in NAFLD.*Trends Pharmacol Sci* 2019; **40**: 506-516 [PMID: 31160124 DOI: 10.1016/j.tips.2019.05.002]

156 **Saran AR**, Dave S, Zarrinpar A. Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease.*Gastroenterology* 2020; **158**: 1948-1966.e1 [PMID: 32061597 DOI: 10.1053/j.gastro.2020.01.050]

157 **Hardy T**, Oakley F, Anstee QM, Day CP. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. *Annu Rev Pathol* 2016; **11**: 451-496 [PMID: 26980160 DOI: 10.1146/annurev-pathol-012615-044224]

158 **Hannah WN Jr**, Torres DM, Harrison SA.Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.*Gastroenterol Hepatol (N Y)* 2016; **12**: 756-763 [PMID: 28035202]

159 **Thiagarajan P**, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. *J Clin Exp Hepatol* 2019; **9**: 515-521 [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002]

160 **Bawden SJ**, Scott RA, Aithal GP. Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.*Dig Dis* 2017; **35**: 314-322 [PMID: 28467990 DOI: 10.1159/000456582]

161 **Cerami E**, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; **2**: 401-404 [PMID: 22588877 DOI: 10.1158/2159-8290.CD-12-0095]

162 **Africa JA**, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, Hou J, Belt PH, Kohil R, Lavine JE, Molleston JP, Newton KP, Whitington PF, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. *Clin Gastroenterol Hepatol* 2018; **16**: 438-446.e1 [PMID: 28286193 DOI: 10.1016/j.cgh.2017.02.030]

**Footnotes**

**Conflict-of-interest statement:** None to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review started:** March 14, 2021

**First decision:** July 18, 2021

**Article in press:** October 14, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chiarioni G, Serban ED **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 Proposed diagnostic criteria of metabolic associated fatty liver disease and key differences with non-alcoholic fatty liver disease definition.** 1Metabolic risk factors include (1) Waist circumference ≥ 102/88 cm in Caucasian men and women (≥ 90/80 cm for Asian men and women); (2) Blood pressure ≥ 130/85 mmHg or on drug treatment; (3) Triglyceride levels ≥ 150 mg/dL (≥ 1.70 mmol/L) or on drug treatment; (4) Plasma high density lipoprotein [HDL < 40 mg/dL (< 1.0 mmol/L) for men and < 50 mg/dL (< 1.3 mmol/L)] for women or on drug treatment; (5) Pre-diabetes [*i.e.*, fasting glucose levels 100 to 125 mg/dL (5.6 to 6.9 mmol/L), or 2-h post-load glucose levels 140 to 199 mg/dL (7.8 to 11.0 mmoL) or HbA1c 5.7% to 6.4% (39 to 47 mmol/moL)]; (6) Homeostasis model assessment of insulin resistance score ≥ 2.5; and (7) Plasma high-sensitivity C-reactive protein level > 2 mg/L. BMI: Body mass index; MAFLD: Metabolic-associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease.



**Figure 2 Key drivers of metabolic-associated fatty liver disease, resulting in disease heterogeneity and its clinical implications.** Genetic predisposition, metabolic health, and environmental factors influence molecular and phenotypical heterogeneity of metabolic-associated fatty liver disease leading to various disease subtypes, variable disease progression, and response to therapy. MAFLD: Metabolic-associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease.



**Figure 3 Natural history of non-alcoholic fatty liver disease (classic and dynamic model).** HCC: Hepatocellular carcinoma; NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis.



**Figure 4 A suggested algorithm for the use of non-invasive tests for risk stratification of patients with suspected non-alcoholic fatty liver disease in clinical practice.** 1Obesity, type 2 diabetes, or metabolic syndrome; 2Estimated prevalence for low, intermediate, and high risks groups; 3Patented serum biomarkers (FibroTest, Fibrometer, or ELF) could be considered in patients with intermediate-risk. ARFI: Acoustic radiation force imaging; LSM: Liver stiffness measurement; MRE: Magnetic resonance elastography; NPV: Negative predictive value; PPV: Positive predictive value; SWE: Shear wave elastography.

**Table 1 Non-invasive tests of hepatic fibrosis and potential confounding factors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Biomarker panel** | **Parameters** | **Validation** | **Prognostic ability** | **Confounding factors/limitations** |
| APRI | AST, platelet | Good | Fair | Large number of individuals fall in the indeterminate range |
| Fibrosis-4 index | Age, AST, ALT, platelet | Very good | Very good | Poor performance in patients aged ≤ 35 yr |
| Low specificity in patients aged ≥ 65 yr |
| Less sensitive in South Asian Population |
| NAFLD fibrosis score | Age, BMI, IFG or diabetes, AST, ALT, platelet, albumin | Very good | Good | Different cutoff values needed for younger or older participants |
| Albumin may decrease in chronic illnesses, malnutrition, nephrotic syndrome and protein-losing enteropathy |
| Less sensitive in South Asian Population |
| Enhanced liver fibrosis panel | PIIINP, HA, TIMP1 | Good | Very good | PIIINP is increased in other fibrotic diseases or bone fracture |
| TIMP1 is increased in cancer and inflammation |
| Not as widely available as non-patented scores and more expensive |
| FibroMeter NAFLD | Age, weight, prothrombin index, ALT, AST, ferritin, fasting glucose | Fair | NA | Prothrombin index affected by anti-coagulants |
| Ferritin is an acute phase protein |
| Glucose is affected by anti-diabetic treatment |
| More validation needed |
| NIS4 | miR-34a-5p, α2-M, YKL-40, and glycated hemoglobin | Fair | NA | Not as widely available as non-patented scores and more expensive |
| More validation is needed |

ALT: Alanine aminotransferase; APRI: AST-to platelet ratio index; AST: Aspartate aminotransferase; BMI: Body mass index; HA: Hyaluronic acid; IFG: Impaired fasting glucose; α2-M: α2 macroglobulin; NA: Not applicable; NAFLD: Non-alcoholic fatty liver disease; PIIINP: Procollagen type III N-terminal peptide; PTI: Prothrombin index; TIMP-1: Tissue inhibitor of matrix metalloproteinase 1.

**Table 2 Liver-targeted therapies in development for the treatment of nonalcoholic fatty liver disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment targets** | **Mechanism of action** | **Agent (oral/injectable)** | **Current status** |
| Metabolism | FXR agonism | Obeticholic acid | Interim analysis of a phase 3 RCT (REGENERATE) showed significant histological improvement[141] |
| Tropifexor (LJN452) | A phase 2 study recently completed (NCT02855164) |
| Cilofexor  | A phase 2 study in patients with NASH showed a decrease in hepatic fat[142] |
| PPAR agonism | Elafibranor  | Interim analysis a phase 3 trial (RESOLVE-IT) failed to show any treatment effect |
| Lanifibranor (IVA337) | A phase 2 study in patients with T2DM and NAFLD is actively recruiting (NCT03459079) |
| Saroglitazar | A phase 2 RCT (EVIDENCES IV) in participants with NAFLD/NASH has shown significant improvement in ALT, LFC, and IR[143] |
| Acetyl-CoA Carboxylase inhibition | PF-05221304 | Improved liver chemistry and liver fat in an RCT[144] |
| GLP-1 agonism | Liraglutide | Only data from small studies have been published and the relative contribution of weight loss and improvement in glycemic control to the observed benefits in NASH are yet to be determined[145-147] |
| Semaglutide | In a phase 2 trial, the primary endpoint (resolution of NASH with no worsening in fibrosis), was met[148] |
| FGF21 agonism | Pegbelfermin (BMS-986036) | A series of phase 2b trials of pegbelfermin are underway |
| MCP2 antagonism | MSDC-0602 K | The EMMINENCE phase 2b trial didn’t meet the primary end point[149] |
| THRβ agonism | Resmetirom (MGL-3196) | A phase 3 study is actively recruiting (NCT03900429) |
| Cell stress and apoptosis | Antioxidant | Vitamin E | Resolution of NASH in some studies, but not all; no impact on fibrosis[150] |
| Pan-caspase inhibition | Emricasan | Phase 2b clinical trials for NASH failed to meet their primary efficacy end points[151] |
| ASK1 inhibition | Selonsertib | Phase 3 STELLAR trials discontinued due to lack of efficacy |
| Inflammation | CCR2/CCR5 inhibition | Cenicriviroc | Phase 3 trial AURORA terminated due to lack of efficacy |
| Inflammasome inhibition | SGM-1019 | A phase 2 study is terminated due to a safety event (NCT03676231)  |
| Fibrosis | LOXL2 inhibition | Simtuzumab | No benefit on histological analysis or on clinical outcomes[152] |
| Gut–liver signaling axis | FGF19 agonism | Aldafermin (NGM282) | In a phase 2 trial of patients with NASH, aldafermin reduced liver fat and produced a trend toward fibrosis improvement[153] |

ACC: Acetyl-CoA carboxylase; ALT: Alanine aminotransferase; ASK1: Apoptosis signal-regulating kinase; CCR: C–C motif chemokine receptor; FGF: Fibroblast growth factor; FXR: Farnesoid X receptor; GLP1: Glucagon-like peptide 1; IR: Insulin resistance; LFC: Liver fat content; LOXL2: Lysyl oxidase homolog 2; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; PPAR: Peroxisome proliferator-activated receptor; THRβ: Thyroid hormone receptor β.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**